Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06686069 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Oral L-arginine 3.32 g a Day on Oxidative Stress Influencing Beta Cell Function and Insulin Resistance.

Study acronym: L-BIOARG
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 13, 2024 (before its estimated November 18, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The objective of this clinical trial is to explore whether L-arginine supplementation with 3.32g/day may enhance antioxidant defenses in overweight and obese patients with pre-diabetes and metabolic syndrome, possibly providing beta cell function and insulin resistance improvement. The primary efficacy endpoint will be to explore the effects of a short-term L-arginine supplementation on AOPP levels and PAI after three months of treatment, based on the rationale explained above. Secondary, the effects of L-arginine supplementation on lipid peroxidation products and antioxidant defenses will be explored. Tertiary, the effects of L-arginine supplementation on insulin resistance and glucose metabolism parameters will be also evaluated.
Trial Details
NCT Number NCT06686069
Lead Sponsor Federico II University
Conditions
(from sponsor)		 Diabetes, Pre-diabetes, Metabolic Syndrome
Related terms Diabetes Mellitus, Glucose Intolerance, Metabolic Syndrome
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov